A study funded by the National Cancer Institute presented the primary results of the SWOG S1011 phase 3 surgical trial, investigating the effectiveness of extended lymphadenectomy, which involves removing additional lymph nodes in patients undergoing radical cystectomy for localized muscle-invasive bladder cancer. The trial found that extended lymphadenectomy did not provide any patient benefit in terms of disease-free survival or overall survival times; however, it did increase the risk of adverse events and post-surgical death.
The study involved 658 patients, and those on the extended lymphadenectomy arm had a higher rate of serious side effects and deaths within 90 days of surgery compared with those who received a standard lymphadenectomy. Despite the expectation of improved outcomes, no significant differences were observed in disease-free or overall survival times between the two groups.
Reference: L S1011: No Extended Node Removal in Bladder Cancer. SWOG. Published May 20, 2023. Accessed July 31, 2023. https://www.swog.org/news-events/news/2023/06/03/s1011-no-extended-node-removal-bladder-cancer
Link: https://www.swog.org/news-events/news/2023/06/03/s1011-no-extended-node-removal-bladder-cancer
